ANEB Anebulo Pharmaceuticals Inc: Net earnings per share for the last 12 months

Public company logo of Anebulo Pharmaceuticals Inc (ANEB)

Anebulo Pharmaceuticals (ANEB) bases its biotech business on the development of ANEB-001, an innovative treatment for emergency cannabinoid overdose assistance. Narrow specialization and a lack of alternatives promise stable revenue from the patented drug. This chart reflects a price trend for EPS (TTM) currently at 33.40. However, future pricing power will depend on test results and the FDA verdict.

ANEB Anebulo Pharmaceuticals Inc Earnings per share for the last twelve months (02/11/2024 - 03/07/2026)

Anebulo Pharmaceuticals - analytical breakdowns and key metrics (ANEB)

- company stock capitalization data:
Core merchandise of Anebulo Pharma

This indicator measures the rate of change in net income per share over the last twelve months, reflecting the actual monetization efficiency of the business model. By analyzing the annual EPS (TTM) change on GURU.Markets, an investor can assess the impact of the Fast Track status of the ANEB-001 drug and the lack of competition on the capitalization of Anebulo Pharmaceuticals (ANEB) through the lens of actual income dynamics.

Competitor analysis